Is there really a ‘big epidemic’ of tick diseases? CDC warns about 7 new viruses

Experts say we can expect each tick season to be worse than the last.

by Linda Carroll, Updated Source: TODAY

A recent afternoon walk turned into a tick attack for a Massachusetts man.

As community forester Derek Lirange was hiking around the Tower Hill Botanic Gardens in Worcester on May 16, he spotted a few ticks on his pants. Within a few more minutes, there were five or six more ticks, followed by more and more. By the end of the hike, he counted 26 ticks.

I hadn’t taken every precaution, such as spraying with insect repellent, but I was wearing long pants and socks,” the 26-year-old told TODAY. “It was a creepy, ongoing discovery.”
Luckily, none had embedded. But the spike of the tick population in the gardens led to the cancellation of a spring walk around the reservoir.
Welcome to the new tick season. No one knows exactly how many ticks are out there, but the skyrocketing cases of tick-borne diseases recently reported by the Centers for Disease Control and Prevention provides indirect evidence that the little bloodsuckers are becoming more numerous, said Alfaro Toledo, an assistant professor in the department of entomology at Rutgers University.
“It’s a big epidemic affecting the entire East Coast,” said Toledo. “Witness the spread of the deer tick to the north and west.”


One big factor leading to the so-called tick explosion is the overall warming trend. But there are several factors beyond warming weather driving the rise in tick numbers, experts say. One is the booming numbers of deer and rodents. Deer, which are the preferred hosts of adult ticks, are increasing in numbers, “because basically there are no predators anymore,” Toledo says.

More deer means more female adult ticks go on to lay eggs.

High numbers of rodents also drive the numbers of ticks. After hatching from eggs, tick larvae attach to rodents to feed and, unfortunately for us, pick up diseases like Lyme and Rocky Mountain Spotted Fever. Once the larvae get their meal of blood, they move on to the next phase of their cycle, the nymph stage, which is when they’re most likely to latch on to a human.
Ticks in the Northeast Rutgers-New Brunswick Center for Vector Biology

Though both nymphs and adults can transmit disease, the nymphs are more likely to do so because of their small size. Adult ticks are big enough to be easy to spot and get rid of before they can pass on diseases like Lyme. Nymphs are much smaller and often attach long enough to transmit disease without our ever spotting them.

And while deer ticks are most likely to be the ones transmitting Lyme and lone star ticks, Rocky Mountain Spotted Fever, dog ticks and a new invader, the Longhorned tick, can also carry and transmit disease.

Experts used to tell people they’d be safe from tick bites if they kept their lawns mowed and stayed out of wooded areas—and that’s still mostly true for deer ticks. But Lone star ticks and dog ticks, which both can carry diseases and bite humans, are perfectly happy roaming through mowed lawns, said Matt Frye, an entomologist at Cornell University.

Frye says we should just accept that every year now is going to be a bad tick year. That means we should get serious about examining our bodies for ticks. “You should do a tick check every day, like you brush your teeth every day,” he said.
Can you spot the five ticks in the muffin? The CDC caused a panic when it tweeted that ticks can be as small as a poppyseed. CDC

The situation isn’t entirely hopeless. Though there are no real natural enemies of ticks, researchers are working on some ingenious ways of knocking their numbers back. One method currently being tested in communities with high numbers of ticks is to treat rodents with tick-killing substances, Frye said. Boxes baited for the rodents give them a dose of the same tick poison used to protect dogs.

The idea is that if you can lower the numbers of ticks that make it to the nymph stage, fewer people will be infected. That method is still being tested, so it won’t help any of us right now.

In the meantime, if you do spot a tick and want to know what kind it is and whether it’s carrying a disease, you can send it to a lab for testing, said Laura Goodman, an assistant research professor at Cornell.

She suggests you place your tick in a sealed, escape-proof container and ship it to Cornell or one of the other certified labs around the country. One of the best ways to kill the tick, Goodman says, is to place the container in your freezer. The shock from going directly from warm weather to freezing temperatures will be enough to do in your tick, she said. writer Meghan Holohan contributed to this report



Gone are the days of frolicking in the yard in shorts and sandals…..

BTW:  Ticks love wood chips.  They use them like leaf-litter and burrow underneath where it’s moist.  They also love Japanese Barberries as other invasives that harbor moisture at the base where they hang out.

In my yard, there has been a chipmunk invasion in all my landscape beds.  They love the natural rock/boulders that have gaps between them.  They burrow into these gaps and create colonies by tunneling into the dirt.  As they work, they deposit ticks everywhere.  I would avoid using these rocks and wood chips as much as possible and steer toward interlinking stones without gaps, weed barrier, and rock.  (Think Fort Knox)

As much as we love nature, keep it away from your living quarters and spray any suspected areas with an acaracide.  And far more than white-footed mice and deer carry these suckers.  Your neighborhood squirrel, chipmunk, opossum, bird, fox, raccoon, and on and on to infinity are scattering ticks.

I’m thankful they are finally admitting that other ticks are problematic.  I’ve always scratched my head when “experts” keep saying the sole perp is the dastardly black legged tick.  Treat every tick like a land mine.  They all exchange fluids with creatures.  Do the math.

When you do go outside into grass, preferably wear white shoes and socks sprayed with permethrin and tuck your light colored pants that have also been sprayed, into your socks.  Ideally you would have a long sleeved white shirt that has also been sprayed and if you are going underneath any trees, shrubs, overhanging plants, wear a hat that has also been sprayed.

This is war, people!

More ideas:

And while climate issues might affect mosquitoes, they don’t affect ticks, according to independent tick researcher John Scott:
This is an important issue to acknowledge as there are only so many research dollars and we need those dollars going toward things that help sick patients.  Enough’s, enough.

Electromagnetic radiation from power lines and phone masts poses ‘credible’ threat to wildlife, report finds


Electromagnetic radiation from power lines, wi-fi, phone masts and broadcast transmitters poses a ‘credible’ threat to wildlife, a new report suggests, as environmentalists warned the 5G roll out could cause greater harm.

An analysis of 97 studies by the EU-funded review body EKLIPSE concluded that radiation is a potential risk to insect and bird orientation and plant health.

However the charity Buglife warned that despite good evidence of the harms there was little research ongoing to assess the impact, or apply pollution limits.

The charity said ‘serious impacts on the environment could not be ruled out’ and called for 5G transmitters to be placed away from street lights, which attract insects, or areas where they could harm wildlife.

Matt Shardlow, CEO of Buglife said: “We apply limits to all types of pollution to protect the habitability of our environment, but as yet, even in Europe, the safe limits of electromagnetic radiation have not been determined, let alone applied.

“There is a credible risk that 5G could impact significantly on wildlife, and that placing transmitters on LED street lamps, which attract nocturnal insects such as moths increases exposure and thereby risk.

“Therefore we call for all 5G pilots to include detailed studies of their influence and impacts on wildlife, and for the results of those studies to be made public.”

As of March, 237 scientists have signed an appeal to the United Nations asking them to take the risks posed by electromagnetic radiation more seriously.

The EKLIPSE report found that the magnetic orientation of birds, mammals and invertebrates such as insects and spiders could be disrupted by electromagnetic radiation (EMR). It also found established that plant metabolism is also altered by EMR.

The authors of the review conclude that there is “an urgent need to strengthen the scientific basis of the knowledge on EMR and their potential impacts on wildlife.

“ In particular, there is a need to base future research on sound, high-quality, replicable experiments so that credible, transparent and easily accessible evidence can inform society and policy-makers to make decisions and frame their policies.”


Effects of Cell Phone Radiation Just Released by the NIH:   The rodents in this study received whole body radiation while in utero, during nursing, and for up to 2 years after weaning.  The rodents were pulsed for 10 minutes of radiation on, 10 minutes off, for 9 hours each day. They used 2G and 3G radiation, the same frequencies and modulations currently in use for texts and voice calls in the United States.

The study findings:

  • Tumors found in rodent’s who were exposed to whole body radio-frequency radiation included: malignant schwannoma of the heart, malignant gliomas of the brain, pituitary adenomas, and adrenal gland pheochromocytomas.
  • It didn’t take long… for example, after only 14 weeks, the researchers found that the right ventricles of the hearts of male rats was already starting to increase abnormally, developing cardiomyopathy.
  • After two years of high exposures to cell phone radiation, exposures were found to affected male rodents more than female rodents: increasing the incidence of malignant schwannoma in the hearts of male rates… while female rats did not have an increased risk of this cancerous tumor. Male rats also had abnormal changes in the prostate gland, liver, pancreas islet cells (the cells responsible for producing insulin) and granular tumors of the brain, and glial cell hyperplasia of the brain.  These changes were not seen in female rats.
  • Both male and female rats had abnormal heart growth (in the right side of the heart, called right ventricular cardiomyopathy.)
  • There were changes in body weight (lowered birth weight in babies born with radiation in utero exposure) as well as genetic damage in both male and female rodents.
  • There was an interesting side effect of the whole body radiation in that the male rats that were exposed to radiation had a longer life span on average than the non-exposed male rats. Life span did not change for the female rats.
  • These changes reflect tumors that have already been reported in humans after prolonged cell phone use, most notably the cancerous gliomas of the brain.

A mother and son’s 9-year roller coaster ride with neuro-Lyme


by Rebecca Zelis

It has been nine years since a diagnosis, and over a decade since a tick-borne disease inflicted itself on my son’s brain.

Imagine riding a roller coaster for nine years, and you’ll understand a little of what parenting a child with neurological Lyme disease feels like; overwhelming anxiety then intense relief, quiet steady climbs followed by startling descents, thinking you’ve reached the end of the ride only to have the carts race past the gate and begin again.

He is doing better each year, but he hurts, he struggles, he knows he is not his best self.

And after ten years, he is angry. When I parented a six-year-old with Lyme disease anger was something we could snuggle, bathe, and read stories to. With a six-foot-one teenager, anger is not something a mom can “fix.”

So instead, I stay positive, organized, and optimistic. I drive hours to doctors’ appointments, confer with therapists, gently remind teachers about 504 plans, assertively remind teachers about 504 plans, cook special foods, and create budgeting miracles in the financial aftermath of a decade of Lyme disease treatment.

I witness his frustration, depression, ‘brain-fog’ and loneliness. I diligently make lists of what I am grateful for. I am extremely patient when people tell me “everything happens for a reason.” I try to remain open to the lessons available in this experience.

What are the lessons? Today, I honestly have no idea. It might be something about being more present in the moment instead of focusing on him getting “better.” It might be about choosing your attitude in difficult circumstances. It might be about patience and grace in the face of adversity. Today, I don’t know what the lesson is because I am so tired. The roller coaster is exhausting. I’d like to get off this ride.

But I won’t get off. I won’t, because he can’t.

When he was in kindergarten and having behavior problems, he used to say, “My body is doing this! It’s not me, it’s my body.” In retrospect it is fascinating that he knew – before the doctors and psychologists, and specialists knew – how Lyme and Bartonella were affecting him.

As a teenager it is much harder to see the separateness between body and identity, between character and productivity. I desperately want him to know who he is without “his body doing this” but that, like so many other things about parenting a teenager with neurological Lyme, is far out of my control.

So, I pray. I never did this before. I pray for his safety. I pray for a cure. I pray that he can salvage some kind of normal childhood in his last few years of high school. I pray that people who aren’t his parents will care about him too. I pray that he will make some friends. I pray that he knows how talented he is. I pray that he doesn’t give up on himself, that he remembers “it’s his body doing this”.

But prayers seem fairly useless on a roller coaster. Prayers don’t make teachers care about him. Prayers don’t make his peers friendlier. Prayers don’t give him moments of joy, or the ability to move his body without pain, or a sense of hope and possibility.

I suspect parents of healthy teenagers experience this too, but with complex and chronic Disease, the stakes seem higher. There are more unknowns and less predictability. The impact of a slice of pizza has to be considered and deliberated, the responsibility of medications delegated and contested. Choices that should be simple aren’t… but at least there are choices. I know parents who would change places with me in a minute, who would gladly be on the roller coaster.

A decade is a long time. Some of those days have been gentle ascents with pleasant views, but on some days, like today, I feel lost, lonely, and pessimistic. Then I think about how long a decade is for a fifteen-year-old. He has lived almost his whole life on the roller coaster.

I am not sure how to end this essay – the metaphor is too easily resolved; “ups and downs” are too informal a conclusion for so much pain. But, Lyme is a lonely disease. Perhaps the lesson today is to simply know that other parents are somewhere out there, on their roller coasters, understanding.

Rebecca Zelis shares what her family has learned from Lyme disease with the hopes of helping others in a similar situation. She can be contacted through her website,



H. R. 5878

To provide for a national strategy to address and overcome Lyme disease and other tick-borne diseases, and for other purposes.


Mr Smith of New Jersey introduced the following bill; which was referred to the Committee on __________________

A Bill

To provide for a national strategy to address and overcome Lyme disease and other tick-boune diseases, and for other purposes.

1 Be it enacted by the Senate and House of Representa-

2 tives of the United States of America in Congress assembled,


4 This Act may be cited as the ‘‘National Lyme and

5 Tick-Borne Diseases Control and Accountability Act of

6 2018’’.




3 (a) ESTABLISHMENT.—The Secretary of Health and

4 Human Services shall establish in the Office of the Sec

5 retary the Office of Oversight and Coordination for Tick

6 Borne Diseases, to be headed by a director appointed by

7 the Secretary—

8 (1) to oversee the creation and updating of an

9 integrated national strategy to overcome Lyme dis

10 ease and other tick-borne diseases; and

11 (2) to oversee and coordinate Lyme disease and

12 other tick-borne disease programs and activities

13 across the agencies and offices of the Department of

14 Health and Human Services.

15 (b) OBJECTIVE OF OFFICE.—In carrying out sub

16 section (a), the Director of the Office shall facilitate and

17 work to ensure accomplishment of the following activities:

18 (1) Expansion and enhancement of epidemiolog-

19 ical research and basic, translational, and clinical bi-

20 ological and biomedical research.

21 (2) Expansion and improvement of the surveil-

22 lance and reporting of Lyme disease and other tick-

23 borne disease, including coinfections with agents of

24 more than one tick-borne disease.

25 (3) Development of effective diagnostic tests to

26 accurately and timely diagnose Lyme disease and


1 other tick-borne disease, including direct detention

2 tests.

3 (4) Development of treatments to cure or im-

4 prove the lives of those who are infected with Lyme

5 disease or other tick-borne disease or who suffer

6 from a tick-induced disorder.

7 (5) Design and conduct of clinical trials of suf-

8 ficient size and duration to support clinical rec-

9 ommendations.

10 (6) Development and maintenance of one or

11 more registries of patients and their experiences re-

12 lating to exposure to, diagnosis for, and treatment

13 of tick-borne disease, including outcomes, which reg-

14 istries shall protect the confidentiality and safety of

15 patient data.

16 (7) Systematic documentation of the experi-

17 ences of health care professionals in diagnosing and

18 treating tick-borne disease, including diagnostic and

19 treatment outcomes.

20 (8) Inclusion individuals with chronic Lyme dis-

21 ease in clinical, research, and service efforts.

22 (9) Coordination with international bodies to in

23 tegrate and inform the fight against Lyme disease

24 and tick-borne disease globally.




3 rying out this section, the Director of the Office shall, as

4 directed by the Secretary, with any modifications made by

5 and as otherwise determined appropriate by the Secretary,

6 oversee and coordinate integration and implementation,

7 into the activities of the Office and the activities and pro-

8 grams of the agencies and offices of the Department of

9 Health and Human Services, of the recommendations to

10 the Secretary and the findings and conclusions in the lat-

11 est report of the Tick-Borne Disease Working Group sub-

12 mitted to the Secretary and congressional committees.


14 rying out this section, the Director of the Office shall give

15 priority to Lyme disease and other tick-borne disease

16 based on assessments of disease burden in the United

17 States.


19 (a) IN GENERAL.—The Secretary, in coordination

20 with the Director of the Office, and in consultation with

21 the Tick-Borne Disease Working Group, the agencies and

22 offices of the Department of Health and Human Services,

23 and other Federal agencies outside of the Department of

24 Health and Human Services as appropriate, shall—


1 (1) not later than 2 years after the date of en-

2 actment of this Act, develop and submit to the Con-

3 gress a national strategy for the conduct and sup-

4 port of Lyme disease and other tick-borne disease or

5 disorder programs and activities; and

6 (2) not less than every 2 years thereafter, up

7 date such strategy.

8 (b) CONTENTS.—The strategy under subsection (a)

9 shall include—

10 (1) proposed budgetary requirements;

11 (2) an assessment of all federally funded pro-

12 grams and activities related to surveillance, diag

13 nosis, treatment, education, or prevention with re-

14 spect to Lyme disease or other tick-borne disease, an

15 evaluation of progress and performance based on

16 mission and purpose, and a description of significant

17 challenges or barriers to performance, including an

18 assessment of Federal grants awarded;

19 (3) a strategy for improving diagnosis, treat-

20 ment, and prevention, including increasing the im-

21 pact of grants awarded by the National Institutes of

22 Health, the Centers for Disease Control and Preven-

23 tion, and other agencies and offices of the Depart-

24 ment of Health and Human Services;


1 (4) a strategy for improving outcomes of indi-

2 viduals with Lyme disease or another tick-borne dis-

3 ease or disorder, including progress related to chron-

4 ic or persistent symptoms and chronic or persistent

5 infection and coinfections, including plans for evalu-

6 ating the potential value of and supporting the con-

7 duct of observational studies, comparative effective-

8 ness research, patient-centered outcomes research,

9 or other real world evidence;

10 (5) the appropriate benchmarks to measure

11 progress in achieving the improvements described in

12 paragraphs (3) and (4);

13 (6) a strategy for improving interactions, co-

14 ordination, and partnerships with other Federal

15 agencies, State and local governments, and global

16 entities; and

17 (7) the latest recommendations of the Tick-

18 Borne Disease Working Group and the steps taken

19 by the agencies and offices of the Department of

20 Health and Human Services to implement those rec-

21 ommendations.






5 (a) IN GENERAL.—The Secretary, in coordination

6 with the Director of the Office, acting as the Secretary

7 determines appropriate through the Director of the Cen-

8 ters for Disease Control and Prevention, the Director of

9 the National Institutes of Health, the Commissioner of

10 Food and Drugs, the Director of the Agency for

11 Healthcare Research and Quality, the Administrator of

12 the Health Resources and Services Administration, the Di-

13 rector of the Indian Health Service, and the heads of other

14 Federal agencies, and in consultation with the Tick-Borne-

15 Disease Working Group, shall provide for—

16 (1) the conduct or support of the activities de-

17 scribed in paragraphs (1) through (8) of subsection

18 (b); and

19 (2) the coordination of all programs and activi-

20 ties of the Department of Health and Human Serv-

21 ices related to Lyme disease and other tick-borne

22 diseases and disorders and Bartonella.

23 (b) ACTIVITIES.—The activities to be conducted or

24 supported under subsection (a)(1) consist of the following:




1 (A) IN GENERAL.—The Secretary shall ex-

2 pand and intensify epidemiological, basic,

3 translational, and clinical research regarding

4 Lyme disease and other tick-borne disease and

5 disorders and bartonellosis to better under-

6 stand—

7 (i) the pathophysiology of Borrelia-

8 burgdorferi and other tick-borne microorga-

9 nisms that are human pathogens and of

10 Bartonella;

11 (ii) pathophysiological changes over

12 time, including pathogen persistence pro-

13 files for patients with differing treatment

14 histories;

15 (iii) activation and deactivation of im-

16 mune system processes; and

17 (iv) whether, and what species of,

18 Bartonella are transmitted by ticks.


20 Secretary shall conduct or support clinical out-

21 comes research to—

22 (i) establish epidemiological research

23 objectives to determine the long-term

24 course of illness for Lyme disease and

25 other tick-borne diseases and disorders;


1 (ii) establish patient-centered treat-

2 ment outcome objectives to allow for the

3 comparative effectiveness of different treat-

4 ment modalities; and

5 (iii) establish patient-centered re-

6 search objectives to help elucidate prom-

7 ising treatment protocols for individuals

8 suspected of harboring coinfections with

9 more than one tick-transmitted pathogen.


11 RESEARCH.—The Secretary shall encourage the

12 solicitation of proposals for collaborative, multi-

13 disciplinary research that would—

14 (i) result in innovative approaches to

15 study emerging scientific opportunities or

16 eliminate gaps in research to improve the

17 research portfolio, including application of

18 successful and promising advances in the

19 study of other types of diseases, such as

20 upregulating or downregulating immune

21 system cells or processes;

22 (ii) outline key research questions,

23 methodologies, and knowledge gaps;

24 (iii) expand the number of research

25 proposals that involve collaboration be-


1 tween 2 or more national research insti-

2 tutes or national centers of the National

3 Institutes of Health, including proposals

4 for research through the Common Fund

5 pursuant to section 402(b)(7) of the Public

6 Health Service Act (42 U.S.C. 282(b)(7))

7 to improve the research portfolio;

8 (iv) expand the number of collabo-

9 rative multi-institutional research grants

10 related to tick-borne disease; and

11 (v) involve additional national re-

12 search institutes and national centers of

13 the National Institutes of Health in intra-

14 mural and extramural research on tick

15 borne disease, such as the National Insti-

16 tute of Neurological Disorders and Stroke

17 conducting or sponsoring research on

18 neurologic Lyme disease.

19 (D) EVALUATION.—Not later than 2 years

20 after the date of enactment of this Act, the Sec

21 retary shall evaluate and make findings on—

22 (i) the feasibility and potential value

23 to the research community of establishing

24 a deidentified human subjects database for


1 Lyme disease and other tick-borne diseases

2 and disorders;

3 (ii) existing government or private

4 biorepositories for Lyme disease and other

5 tick-borne diseases and disorders and

6 whether—

7 (I) specimens and samples are

8 adequate and available to meet re-

9 searcher needs; or

10 (II) there are problems or chal-

11 lenges for researcher acquisition of

12 samples and specimens; and

13 (iii) the scope and use of specimens

14 and samples from cadavers, the questions

15 and answers such research may provide,

16 and the need for additional support of re-

17 searchers using cadaver specimens.

18 (E) PRIORITY.—In carrying out this para-

19 graph, the Secretary shall make it a priority to

20 determine the extent of post treatment persist-

21 ence of Borrelia burgdorferi and the clinical sig-

22 nificance of such persistence.




1 (A) IN GENERAL.—The Secretary, in co-

2 operation with the Director of the Office, and

3 acting through the Directors of the Centers for

4 Disease Control and Prevention and the Direc

5 tor of the National Institutes of Health, shall

6 conduct and support research to—

7 (i) provide for the timely evaluation of

8 promising new and improved diagnostic

9 methods, including direct-detection tests,

10 antibody-based tests, and tests based on

11 biosignature and biomarker profiles to

12 make a specific diagnosis or aid in dif-

13 ferential diagnoses;

14 (ii) improve the sensitivity of Lyme

15 disease tests at all stages of disease pro-

16 gression;

17 (iii) develop a Lyme disease test capa-

18 ble of distinguishing between past and ac-

19 tive infections;

20 (iv) improve timely, sensitive, and spe-

21 cific diagnostic tools and tests for Rocky

22 Mountain spotted fever; and

23 (v) improve the performance (timeli-

24 ness and accuracy) of tools and tests for


1 other tick-borne diseases found in the

2 United States.


4 ANCE.—The Secretary shall direct the Commis-

5 sioner of Food and Drugs to design and pro-

6 pose or implement, as appropriate within the

7 authorities and public health priorities vested in

8 the Secretary by other provisions of law, strate-

9 gies for facilitating and expediting the clearance

10 or approval of improved diagnostic tests for

11 Lyme disease and other tick-borne disease, par-

12 ticularly where—

13 (i) there are no cleared diagnostic

14 tests; or

15 (ii) cleared diagnostic tests lack a

16 high level of specificity or sensitivity or are

17 unable to confirm the presence or absence

18 of active infection.


20 CINES.—The Secretary shall—

21 (A) ensure the safety and efficacy of any

22 new, renewed, or modified human vaccine for

23 Lyme disease, other tick-borne disease, or a

24 combination of such diseases; and


1 (B) require the Commissioner of Food and

2 Drugs to submit to the Secretary prior to final

3 approval of the vaccine being reviewed, a report,

4 with appropriate provisions for commercial con

5 fidentiality, detailing the safety of the vaccine

6 and contrasting its safety profile based on its

7 mechanisms of action to safety concerns ex-

8 pressed to the Food and Drug Administration

9 regarding the human vaccine withdrawn from

10 the market in 2002 and how those concerns

11 with the withdrawn vaccine have been addressed

12 or why they are not relevant.




16 (A) IN GENERAL.—The Secretary shall—

17 (i) establish and maintain a statis-

18 tically sound, scientifically credible surveil-

19 lance system to be known as the National

20 Tick-Borne Disease Surveillance System;

21 (ii) enhance and expand infrastructure

22 and activities to track the epidemiology of

23 Lyme disease and other tick-borne diseases

24 and disorders; and


1 (iii) incorporate information obtained

2 through such activities into the National

3 Tick-Borne Disease Surveillance System.

4 (B) RESEARCH.—The Secretary shall en-

5 sure that the National Tick-Borne Disease Sur-

6 veillance System is designed in a manner that

7 facilitates further research on Lyme disease and

8 other tick-borne diseases and disorders.

9 (C) CONTENT.—In carrying out subpara-

10 graph (A), the Secretary—

11 (i) shall provide for the collection and

12 storage of information on the incidence

13 and prevalence of tick-borne disease in the

14 United States—

15 (I) while continuing to support

16 activities in the 14 States with the

17 highest number of reported cases of

18 Lyme disease, and intensifying efforts

19 in other States where Lyme disease

20 has been reported and where all re-

21 ported cases cannot be affirmatively

22 associated with out-of-State travel in

23 order to better determine where the

24 disease is emerging;


1 (II) working with the States and

2 treating physicians, in consultation

3 with the Council of State and Terri-

4 torial Epidemiologists (in this clause

5 referred to as the ‘‘CSTE’’), to im-

6 prove evaluation of the feasibility of

7 capturing data on cases that do not

8 meet surveillance criteria of the CSTE

9 and the Centers for Disease Control

10 and Prevention;

11 (III) in consultation with the

12 CSTE, working with States that are

13 using averaging or similar techniques

14 to estimate case reports to ensure that

15 data produced by that process are

16 able to be reported out by the Centers

17 for Disease Control and Prevention;

18 (IV) in consultation with the

19 CSTE, working with the States to en-

20 courage and improve laboratory re-

21 porting of Lyme disease and other

22 tick-borne diseases, and evaluate the

23 feasibility of creating a national uni-

24 form reporting system including man-


1 datory reporting by States and physi

2 cians and laboratories in each State;

3 (V) including in the surveillance

4 system bartonellosis transmitted by

5 any vector and, if it is known, by the

6 vector of transmission; and

7 (VI) tracking incidence and prev-

8 alence data for tick-borne disorders;

9 (ii) to the extent practicable, shall

10 provide for the collection and storage of

11 other available information on Lyme dis-

12 ease and other tick-borne diseases and dis-

13 orders, including information related to

14 persons who have been diagnosed with and

15 treated for tick-borne disease who choose

16 to participate, such as—

17 (I) demographics, such as age,

18 race, sex, geographic location, and

19 other information, as appropriate;

20 (II) family history and experience

21 with tick-borne disease or tick induced

22 disorder;

23 (III) history of exposure and

24 known tick bites;


1 (IV) progression of signs and

2 symptoms;

3 (V) diagnostic and treatment his-

4 tory and outcomes; and

5 (VI) additional screening con-

6 ducted and related data, such as bio-

7 logical markers.

8 (D) CONSULTATION.—In carrying out this

9 paragraph, the Secretary shall consult with in-

10 dividuals with appropriate expertise, which may

11 include—

12 (i) epidemiologists with experience in

13 disease surveillance or registries;

14 (ii) representatives of national patient

15 advocacy and research organizations that

16 focus on tick-borne disease and have dem-

17 onstrated experience in research, data col-

18 lection, or patient access to care;

19 (iii) health information technology ex-

20 perts or other information management

21 specialists;

22 (iv) clinicians with expertise in Lyme

23 disease or other tick-borne diseases or dis-

24 orders; and


1 (v) research scientists with experience

2 conducting translational research or uti-

3 lizing surveillance systems for scientific re-

4 search purposes.

5 (E) GRANTS.—The Secretary may award

6 grants to, or enter into contracts or cooperative

7 agreements with, public or private nonprofit en-

8 tities to carry out activities under this para-

9 graph.


11 STATE, AND LOCAL AGENCIES.—Subject to sub-

12 paragraph (H), the Secretary shall—

13 (i) establish agreements and mecha-

14 nisms, as appropriate, for improved col-

15 lecting and reporting of tick-borne disease

16 surveillance data under subparagraphs (A),

17 (B), and clause (i) of subparagraph (C)

18 and other available information under

19 clause (ii) of subparagraph (C) from com-

20 munity health centers funded by the

21 Health Resources and Services Administra-

22 tion and medical facilities of the Indian

23 Health Service;

24 (ii) establish formal agreements, as

25 appropriate and may be worked out, to


1 provide for improved collection and report-

2 ing of surveillance data under subpara-

3 graphs (A), (B) or clause (i) of subpara-

4 graph (C) and other available information

5 under clause (ii) of subparagraph (C), ob-

6 tained from hospitals and medical clinics

7 run by other Federal departments and

8 agencies;

9 (iii) make information and analysis in

10 the National Tick-Borne Disease Surveil-

11 lance System available, as appropriate, to

12 all components of the Department of

13 Health and Human Services, to other Fed-

14 eral agencies, and to State and local agen-

15 cies; and

16 (iv) identify, build upon, leverage, and

17 coordinate among existing data and sur-

18 veillance systems, surveys, registries, and

19 other Federal public health infrastructure,

20 wherever practicable.

21 (G) PUBLIC ACCESS.—Subject to subpara-

22 graph (H), the Secretary shall ensure that in

23 formation and analysis in the National Tick-

24 Borne Disease Surveillance System are avail-

25 able, as appropriate, to the public and other in-

21 1 terested parties on the website of the Depart-

2 ment of Health and Human Services.

3 (H) PRIVACY.—The Secretary shall ensure

4 that information and analysis in the National

5 Tick-Borne Disease Surveillance System are

6 made available only to the extent permitted by

7 applicable Federal and State law, and in a

8 manner that protects personal privacy, to the

9 extent required by applicable Federal and State

10 privacy law, at a minimum.



13 CATION.—The Secretary shall increase public

14 education related to Lyme disease and other

15 tick-borne diseases and disorders through the

16 expansion of the community-based education

17 programs of the Centers for Disease Control

18 and Prevention to include development and

19 publication of a consumer tick disease pam-

20 phlet, available online and by hard copy, ad-

21 dressing— 22 (i) ticks and tick-borne diseases com-

23 mon to the geographic area, tick-borne dis-

24 ease that could be acquired while on do-

25 mestic or international travel, and ticks


1 that, while not common to the geographic

2 area, could migrate to the area;

3 (ii) signs and symptoms of such tick-

4 borne disease;

5 (iii) tick removal instructions;

6 (iv) the most effective actions individ-

7 uals can take to reduce risk of exposure to

8 ticks and risk of disease transmission; and

9 (v) additional community-based ac-

10 tions to reduce risk of exposure to ticks.

11 (B) COORDINATION.—In carrying out sub-

12 paragraph (A), the Secretary, acting through

13 the Director of the Centers for Disease Control

14 and Prevention, shall coordinate with legally in

15 corporated Lyme disease or other tick-borne

16 disease organizations.

17 (C) DISSEMINATION.—The Administrator

18 of the Health Resources and Services Adminis-

19 tration and the Director of the Indian Health

20 Service shall make available in rural health cen-

21 ters and clinics which they operate or fund—

22 (i) the consumer tick disease pam-

23 phlets developed under subparagraph (A);

24 or


1 (ii) such other appropriate consumer

2 tick disease pamphlets as the Administra-

3 tion or Service may develop or acquire.


5 retary shall carry out a physician education

6 program that addresses the full spectrum of sci-

7 entific research related to Lyme disease and

8 other tick-borne diseases and disorders, includ-

9 ing—

10 (i) the role of clinical diagnosis;

11 (ii) the limitations of serological diag-

12 nostic tests;

13 (iii) enhanced, validated diagnostics

14 available from laboratories certified under

15 section 353 of the Public Health Service

16 Act (42 U.S.C. 263a) that may aid the

17 physician;

18 (iv) guidelines available on the Na-

19 tional Guideline Clearinghouse;

20 (v) the voluntary nature of clinical

21 practice guidelines;

22 (vi) the complexities presented by co-

23 infections relating to symptomology, diag

24 nosis, and treatment, including prudently


1 acting in the patient’s interest in non- or

2 low-incidence States; and

3 (vii) the identification of significant

4 research gaps most impacting diagnosis

5 and treatment, and significant research

6 being conducted to address those gaps.


8 EDUCATION PROGRAM.—The Secretary of

9 Health and Human Services shall—

10 (i) conduct a public meeting to solicit

11 input for the design of the physician edu-

12 cation program under subparagraph (D);

13 (ii) give the public notice of such

14 meeting at least 45 days in advance;

15 (iii) also solicit input on the design of

16 the physician education program from the

17 Tick-Borne Disease Working Group;

18 (iv) publish a proposed syllabus for

19 the physician education program not more

20 than 120 days after the public meeting;

21 (v) allow for a 60-day public comment

22 period before publishing such syllabus in

23 final form; and

24 (vi) publish on the public website of

25 the Department of Health and Human


1 Services a summary of the comments re-

2 ceived from the public under this subpara-

3 graph before conducting the first training

4 program under subparagraph (D).





9 The Secretary, in coordination with the Direc-

10 tor of the Office, acting through the Director of

11 the Centers for Disease Control and Prevention

12 and other agencies and offices of the Depart-

13 ment of Health and Human Services as appro-

14 priate, shall—

15 (i) not later than 180 days after the

16 date of enactment of this Act, provide a re-

17 port to the Congress describing the tick

18 surveillance and pathogen testing activities

19 of the Department and entities funded by

20 the Department, including—

21 (I) a detailed description of the

22 tick surveillance and tick pathogen

23 testing activities and planned activi-

24 ties of the Vector-Borne Disease Re-

25 gional Centers of Excellence as estab-


1 lished under Funding Opportunity

2 Announcement RFA–CK–17–005,

3 Catalog of Federal Domestic Assist-

4 ance Number 93.084; and

5 (II) within such description, the

6 roles of participating academic, gov-

7 ernmental, and private institutions;

8 (ii) not later than 2 years after the

9 date of enactment of this Act, in consulta-

10 tion and coordination with other Federal

11 agencies and State and local government

12 agencies, as appropriate, and established

13 academic or nonprofit tick-testing centers,

14 develop a framework and an implementa-

15 tion plan for a comprehensive nationwide

16 strategy for the surveillance and testing of

17 ticks for human pathogens and microorga-

18 nisms with unknown pathogenicity, includ-

19 ing a plan for a network of tick identifica-

20 tion and testing laboratories;

21 (iii) not later than 2 years after the

22 date of enactment of this Act, establish

23 agreements and procedures for sharing

24 data on surveillance and testing of ticks


1 with other Federal departments and agen-

2 cies engaged in such activities; and

3 (iv) consult and coordinate with the

4 American Veterinary Medical Association

5 and the Companion Animal Parasite Coun-

6 cil on obtaining and sharing data on the

7 surveillance and testing of ticks and tick

8 borne pathogens, including geographic in

9 formation from veterinary encounters.

10 (B) INVESTIGATION.—In carrying out sub-

11 paragraph (A), the Secretary, in coordination

12 with the Director of the Office, acting through

13 the Director of the Centers for Disease Control

14 and Prevention, in consultation and coordina-

15 tion with other Federal agencies that conduct

16 or support tick surveillance or testing activities,

17 as appropriate, and public and private labora-

18 tories, shall—

19 (i) investigate and, where appropriate,

20 promote the use of advanced new tech-

21 nologies, such as tools to discover all

22 known and all previously unidentified

23 microorganisms in a vector; and

24 (ii) while being informed by previous

25 surveillance studies, allow for the possi-


1 bility of rapid geographic migration of tick

2 vectors and pathogens and unexpected

3 findings.


5 The Secretary, in coordination with the Direc-

6 tor of the Office, acting through the Director of

7 the Centers for Disease Control and Prevention

8 and the Director of the National Institutes of

9 Health, shall, as appropriate and pursuant to

10 authorities vested in the Secretary by other pro-

11 visions of law, support activities of and coordi-

12 nate and share, information with other Federal,

13 State, and local government agencies, involved

14 or interested in tick prevention and control ac-

15 tivities on—

16 (i) the development of safer and more

17 effective tick repellents, both natural and

18 chemical;

19 (ii) the use of acaricides or other

20 chemical interventions;

21 (iii) nonchemical environmental meas-

22 ures to lessen human exposure to ticks;

23 (iv) genetic therapies for vectors or

24 animal hosts to interfere with the life cycle

25 of pathogens; and


1 (v) the development of vector or res-

2 ervoir host vaccines.

3 (D) Leveraging existing tick management

4 resources.—In carrying out this paragraph, the

5 Secretary, in coordination with the Director of

6 the Office, acting through the Director of the

7 Centers for Disease Control and Prevention,

8 shall identify, build upon, leverage, and coordi-

9 nate among existing tick surveillance, testing,

10 and management resources and infrastructure

11 wherever practicable.

12 (E) Public access to data.—In carrying out

13 this paragraph, the Secretary, in coordination

14 with the Director of the Office, acting through

15 the Director of the Centers for Disease Control

16 and Prevention, in coordination and consulta-

17 tion with other Federal agencies and State and

18 local agencies as appropriate, make data on tick

19 surveillance, testing, control and prevention

20 available to the public on the website of the De-

21 partment of Health and Human Services.



24 (A) SENSE OF CONGRESS.—It is the sense

25 of the Congress that public meetings, con-


1 ferences, symposia, and seminars (including

2 webinars) sponsored by the Federal Govern-

3 ment are a valuable input to strategic and oper-

4 ational programmatic planning within Federal

5 agencies and to the work of the Tick-Borne

6 Disease Working Group.

7 (B) REQUIREMENTS.—The Secretary and

8 the Director of the Office, in cooperation with

9 the Director of the Centers for Disease Control

10 and Prevention, the Director of the National

11 Institutes of Health, and the Tick-Borne Dis-

12 ease Working Group, shall—

13 (i) no later than 24 months after the

14 date of enactment of this Act, sponsor a

15 state-of-the-science conference on Lyme

16 disease and other tick-borne disease includ-

17 ing identification of research gaps and top

18 research priorities;

19 (ii) for any scientific or medical con-

20 ference on Lyme disease or other tick

21 borne disease that is organized, sponsored,

22 or paid for by the Department of Health

23 and Human Services, ensure that a con-

24 trolling statement of work and significant

25 modifications thereto, whether in the con


1 tract or as a separate document, issued to

2 the vendor organizing or conducting the

3 conference are in writing and made avail-

4 able to the public prior to the conference;

5 (iii) not later than 120 days after the

6 conclusion of the conference under clause

7 (i), make available a final report on the

8 conference to the Tick-Borne Disease

9 Working Group and to the public;

10 (iv) not later than 18 months after

11 the date of enactment of this Act, working

12 through the Director of the Agency for

13 Healthcare Research and Quality, sponsor

14 a symposium on the use of real-world evi-

15 dence (meaning data from sources other

16 than randomized clinical trials, such as ob-

17 servational studies, comparative effective-

18 ness and patient-centered outcomes re-

19 search, and patient clinical data or human

20 subject data), including the standards and

21 methodologies for collection and analysis of

22 real-world evidence in managing Lyme dis-

23 ease and other tick-borne disease;

24 (v) include in such symposium identi-

25 fication and analysis of existing data


1 sources, such as patient registries and

2 human subjects’ databases;

3 (vi) sponsor a researcher workshop on

4 challenges and solutions for clinical trial

5 design and implementation for Lyme dis-

6 ease to be held no later than 24 months

7 after the date of enactment of this Act,

8 which workshop may consider other tick

9 borne disease or coinfections with more

10 than one tick-borne pathogen as may be

11 feasible and practicable;

12 (vii) not later than 9 months after the

13 date of enactment of this Act, in consulta-

14 tion with the Tick-Borne Disease Working

15 Group, design a survey instrument or in-

16 struments targeted to patients and patient

17 advocates, physicians and health care pro-

18 viders, and researchers regarding rec-

19 ommended subjects and agendas for feder-

20 ally sponsored meetings, conferences, and

21 seminars, including webinars, on Lyme dis-

22 ease and other tick-borne disease;

23 (viii) not later than 6 months after

24 the conduct of the survey, provide an anal-

25 ysis of the results of the survey to the


1 Tick-Borne Disease Working Group and

2 publish such results in the Federal Reg-

3 ister for a 60-day public comment period;

4 and

5 (ix) provide a final analysis and a pro-

6 posed schedule and agenda for public

7 meetings, conferences, and seminars, in

8 cluding webinars, for incorporation into the

9 national strategy under section 3 as appro-

10 priate and to the Tick-Borne Disease

11 Working Group.


13 Secretary, in coordination with the Director of the

14 Office, shall direct the Director of the Agency for

15 Healthcare Research and Quality to assemble a bib-

16 liography of peer-reviewed literature of tick-borne

17 diseases and disorders in the United States, as well

18 as for bartonellosis from whatever cause, appro-

19 priately organized for use by the scientific commu-

20 nity, treating physicians, and the public. The bibliog-

21 raphy should include literature relating to possible

22 mechanisms of persistent infection with Borrelia

23 burgdorferi or other types of Borrelia.


25 ducting and supporting activities under this section, the


1 Secretary shall give priority to Lyme disease and other

2 tick-borne diseases based on assessments of disease bur-

3 den in the United States.


5 (a) IN GENERAL.—Not later than 24 months after

6 the date of the enactment of this Act, and biennially there-

7 after, the Secretary shall submit to the Congress a report

8 on the activities carried out under this Act and the activi-

9 ties of the Tick-Borne Disease Working Group.

10 (b) CONTENT.—Reports under subsection (a) shall

11 contain—

12 (1) a scientifically qualified assessment of Lyme

13 disease and other tick-borne disease, including a

14 summary of prevalence, geography, important expo-

15 sure characteristics, disease stages and manifesta-

16 tions or symptoms of those stages, based on a syn-

17 thesis of the broad spectrum of empirical evidence of

18 treating physicians, as well as published peer-re-

19 viewed data, to include for each tick-borne disease a

20 state-of-the-science diagnosis and treatment;

21 (2) a description of all programs and activities

22 funded by the Department of Health and Human

23 Services that are related to the surveillance, diag-

24 nosis, treatment, education, or prevention of Lyme

25 disease or other tick-borne disease, and an evalua


1 tion of progress and performance based on mission

2 and purpose, and discussion of significant challenges

3 or barriers to performance, to include—

4 (A) for the initial report under this section,

5 a description of the intramural and extramural

6 research portfolios of the Centers for Disease

7 Control and Prevention, the National Institutes

8 of Health, and other agencies and offices of the

9 Department of Health and Human Services

10 which conducted or contracted for research

11 projects related to Lyme disease or on other

12 tick-borne disease or disorder, including infor-

13 mation on— 14 (i) the award amount, institution, pri-

15 mary investigator, principal investigative

16 question or questions, and significant con-

17 clusions; and

18 (ii) studies that received Federal

19 funds and were terminated, in progress, or

20 initiated in the fiscal year including the

21 date of enactment of this Act and the 5

22 prior fiscal years;

23 (B) for reports in subsequent years, all of

24 the information described in subparagraph (A),

25 except the reference in subparagraph (A)(ii) to


1 Federal funds terminated, in progress, or

2 awarded in the 6 prior fiscal years shall be

3 treated as reference to such funds in the 2 prior

4 fiscal years;

5 (C) a status and summary report on the

6 National Tick-Borne Disease Surveillance Sys-

7 tem, including—

8 (i) the type of information collected

9 and stored in the System;

10 (ii) the use, distribution, and avail-

11 ability of such information, including

12 guidelines for such use; and

13 (iii) the use and coordination of sur-

14 veillance and patient information data-

15 bases; and

16 (D) information on agreements, partner-

17 ships, cooperation, coordination, and data shar-

18 ing with external entities, such as State and

19 local governments, other Federal agencies,

20 working groups, and global entities;

21 (3) a description of major externally funded re-

22 search, surveillance, education, or other programs

23 and initiatives impacting the management or science

24 of tick-borne disease;


1 (4) recommendations for addressing research

2 gaps in scientific understanding of Lyme disease and

3 other tick-borne diseases and disorders and relevant

4 to development of effective diagnostic tools and

5 treatment protocols for Lyme disease and other tick-

6 borne diseases and disorders;

7 (5) a description of clinical practice guidelines

8 for any tick-borne disease published on the National

9 Guideline Clearinghouse;

10 (6) recommendations for addressing research

11 gaps in tick biology and tick management;

12 (7) a description of activities for the promotion

13 of public awareness and physician education initia-

14 tives to improve the knowledge of health care pro

15 viders and the public in support of clinical and be-

16 havioral decision making in relationship to Lyme

17 disease and other tick-borne disease; and

18 (8) a copy of the most recent annual report

19 issued by the Tick-Borne Disease Working Group

20 and an assessment of progress in achieving rec-

21 ommendations of that Working Group.

22 (c) BIENNIAL REPORTS OF NIH.—The Secretary

23 shall ensure that each biennial report under title III of

24 the Public Health Service Act (42 U.S.C. 241 et seq.) or

25 each triennial report under section 403 of such Act (42


1 U.S.C. 283) includes information on actions undertaken

2 by the National Institutes of Health to carry out research

3 with respect to Lyme disease and other tick-borne disease.


5 In this Act: 6 (1) BARTONELLOSIS.—The term

7 ‘‘bartonellosis’’ means disease caused by Bartonella

8 infection from any vector or source, unless otherwise

9 specified.

10 (2) DISORDER.—The term ‘‘disorder’’ means a

11 disorder caused by ticks, but not inducing human in-

12 fection, such as tick paralysis and Alpha-Gal meat

13 allergy.

14 (3) OFFICE.—The term ‘‘Office’’ means the Of-

15 fice of Oversight and Coordination for Tick-Borne

16 Diseases established under section 2.

17 (4) OTHER FEDERAL AGENCY.—Other Federal

18 agency means a Federal Department, agency or of

19 fice outside of the U.S. Department of Health and

20 Human Services.

21 (5) SECRETARY.—The term ‘‘Secretary’’ means

22 the Secretary of Health and Human Services.

23 (6) TICK-BORNE DISEASE.—The term ‘‘tick

24 borne disease’’ means a disease that is known to be

25 transmitted by ticks in the United States, unless


1 otherwise specified, or that may be discovered to be

2 transmitted by ticks in the United States.


4 The term ‘‘Tick-Borne Disease Working Group’’

5 means the Tick-Borne Disease Working Group es-

6 tablished under section 2062 of the 21st Century

7 Cures Act (42 U.S.C. 284s).



Infect Drug Resist. 2018 Apr 26;11:625-628. doi: 10.2147/IDR.S162048. eCollection 2018.

A case of Lyme disease in a Japanese woman.

Seki M1, Watanabe Y2, Kawabata H3.

This report presents the case of a Japanese patient who developed Lyme disease. The patient was a 44-year-old woman who had general fatigue and the inability to open her mouth. She was initially suspected of having mild tetanus with lockjaw; however, she reported a past history of a tick bite while camping in the USA and had erythema migrans 2 months before this visit. Finally, Lyme disease was serologically confirmed. A few cases of Lyme disease are annually reported in Japan; however, this infectious disease should also be suspected.



Kudos to the researchers for refraining from stating that her inability to open her mouth is an atypical presentation or rare.  Nothing about this rat snarl is rare anymore.

 Just look around.  By Aristos Georgiou, 5/18/18


GettyImages-619207386File photo: A mosquito is seen on a man legs in Yangon, Myanmar, on October 30, 2016. Mosquito saliva contains proteins which may significantly alter our immune system, according to new research.YE AUNG THU/AFP/GETTY IMAGES

blob: (News video here)

When mosquitoes bite you, hundreds of different proteins present in their saliva enter your bloodstream, in addition to any pathogens they may be carrying.

Some of these proteins help the mosquito to suck blood from you. But they may also have more wide-ranging effects, increasing the severity of any diseases that the mosquitos are carrying by causing a significant immune response that can last for days after a bite, according to new research.

In a new study, published in the journal PLOS Neglected Tropical Diseases, scientists from Baylor College of Medicine examined the effects of mosquito bites on human immune cells. To do this they bioengineered mice using human stem cells, which effectively gave the rodents some features of a human immune system. These features included a complete set of human white blood cells, including the so-called ‘T cells’ that fight disease.

The mice were bitten by mosquitoes uninfected with any pathogens in a lab environment. Afterwards, the scientists analyzed any change in the functioning of the humanized immune cells.

They found that the mosquito spit alone produced an immune response involving more types of cells and lasting far longer than expected. In fact, the scientists detected immune cells traveling to the site of the bite up to seven days after it occurred. Furthermore, the immune response was observed in various tissue types, including the blood, skin and bone marrow.

“The biological significance of these changes remains to be determined, but it might explain how some pathogens, such as viruses, can spread through the body in these cells, replicate to higher extents, and even remain in some tissues for far longer than detected in blood,” the researchers wrote in the study.

Previous studies have also indicated that some properties of a mosquito bite, including its saliva, may exacerbate diseases that the insects carry.

For example, mouse experiments have shown that infections caused by a mosquito bite are often more severe than those caused by injecting the same parasite with a needle. However, whether or not the results of previous studies looking into this issue would translate to humans is an open question, as the experiments used bioengineered mice that provide a less accurate model of our immune system in comparison to the mice used in the latest study.

Mosquitoes and the pathogens they transmit are a growing public health concern. Around the world, 750,000 people die every year from mosquito-borne diseases—including malaria, dengue, West Nile, Zika and chikungunya.

Treatment options are often limited for these diseases and their incidence is only expected to rise in the next few decades, as the host ranges of multiple mosquito species increase due to climate change.

“Understanding how mosquito saliva interacts with the human immune system not only helps us understand mechanisms of disease pathogenesis but also could provide possibilities for treatments,” the researchers wrote in the study.

“If we know which mosquito saliva components enhance pathogenesis of diseases, we could create a human vaccine to counteract these effects for multiple infections,” they said.



What does this mean for Lyme/MSIDS patients?  According to this study, mosquitoes carry Lyme disease (borrelia):

Here is an excellent read by Dr. Sponaugle on the study:  He explains that the fact mosquitoes bite quickly makes some question their ability to transmit Bb; however, Sponaugle states, “Mosquitoes might have the equipment after all to enable Borrelia spirochetes the ability to survive for the durations necessary to be viable vectors of Lyme disease.”

Reading this current information on the various proteins & other pathogens present in their saliva altering human immune systems certainly screams for more intense study of the potential not only of spreading Bb but of amplifying all pathogens in the mosquito as well as the human.  The combination of tick and mosquito transmission would certainly help explain the far-ranging (world-wide) transmission rates of Lyme/MSIDS.  And, what about the other coinfections?  Much must be done with clear, unbiased studies starting at ground zero.

We need transmission studies more than we need climate studies.  People are dying out here.

For more:

GMO mosquitoes:

Wolbachia as a biocontrol:  Ticks carry worms and transmit them to humans.  Here’s what’s scary about Wolbachia: “Dogs treated for heart worm (D. immitis) have trouble due to the heart worm medication causing Wolbachia to be released into the blood and tissues causing severe Inflammation in pulmonary artery endothelium which may form thrombi and interstitial inflammation. Wolbachia also activates pro inflammatory cytokines.”  Nobody’s talking about what this could do to humans – particularly humans with worms.

GMO Mice:

Regarding tick eradication, controlled burns are 78-98% effective, yet are not huge money makers and isn’t garnering support.  It’s up to We the People to spread the truth:

According to Lyme Advocate Carl Tuttle, legislation has not helped end the unimaginable pain and suffering that Lyme/MSIDS causes for the victims of this injustice.  He recommends we all write our own letters supporting a congressional investigation and send copies to Chris Smith (Rep. New Jersey) and Collin Peterson (Rep. Minnesota) as well.

Also, Jenna Luche-Thayer has written a review of House Bill 5878 which will supposedly, “Provide for a national strategy to address and overcome Lyme Disease and other tick-borne diseases, and for other purposes.”  She too is concerned whether it will truly serve the Lyme patient community or just “enrich certain individuals and entities.”  In the following link she exposes Working Group Chair John Aucott’s 2015 patent for measuring cytokines and the fact he could make money while possibly affecting if and which patients receive extended antimicrobials and biologics.  (Go here for details)

Following is Tuttle’s letter as an example.  Please use your own story, details and facts when writing your letter:

May 20, 2018

The Honorable Chris Smith
United States House of Representatives
2373 Rayburn House Office Building
Washington, D.C. 20515

Dear Representative Smith,

Thank you for recognizing the seriousness of Lyme disease! Patient experience as you know is describing an illness that is destroying lives, ending careers, causing death and disability while leaving victims in financial ruin.

Lyme disease is capable of producing sudden death with no warning signs; [1,2,3] heart damage requiring transplant, [4] paralysis with seizures, [5] lymphoma [6] and persistent infection after antibiotic treatment [7,8,9,10,11] along with congenital transmission [12] and ability to create wheelchair bound patients [13] yet there are no Public Service Announcements informing the public that you could become horribly disabled or die from Lyme disease.

“Spirochetes disseminate to the lymph nodes, bone marrow, spleen and brain within a week of infection [A]. Lymph node germinal centers, where B cells are supposed to mature and be assigned an immune system function, are rendered incompetent [B]”

A. Lymphoadenopathy during Lyme Borreliosis Is Caused by Spirochete Migration-Induced Specific B Cell Activation

B. Suppression of Long-Lived Humoral Immunity Following Borrelia burgdorferi Infection

*Immune suppression allows latent viruses to rear their ugly heads (Epstein Barr, herpes etc.)


Through an elaborate racketeering scheme the disease has been downplayed because it became “too expensive to treat” as outlined in the SHRADER & ASSOCIATES, LLP court document.

The court document can be found at the following link:

We are dealing with a life-altering/life-threatening infection with faulty/misleading antibody tests, inadequate treatment, no medical training and absolutely no disease control; a public health disaster. And to make things worse, our blood supply is most likely full of Lyme disease.

A plague denied; essentially classifying this disease as a low-risk and non-urgent health threat.

A second lawsuit was filed recently against the CDC; additional evidence that the Centers for Disease Control here in the United States has mishandled Lyme disease for the past three decades. Dr. Sin Lee of Milford Molecular Diagnostics identified a case of chronic Lyme disease through his DNA sequencing technology and published his findings. After Lee published this case all communication with the CDC ended abruptly. It appears that the CDC does not want direct detection methods for the diagnosis of Lyme as this would upend the status quo that chronic Lyme does not exist.


$57.1 Million Lyme Disease Lawsuit Filed Against CDC


I would like to call attention to the attached pilot study recently identifying chronic Lyme disease in twelve patients from Canada.

Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease

All of these patients were culture positive for infection (genital secretions, skin and blood) even after multiple years on antibiotics so there was no relief from current antimicrobials. Some of these patients had taken as many as eleven different types of antibiotics.

Persistent Lyme disease has been intentionally/deceitfully suppressed for decades as described in the attached letter to past CDC Director Brenda Fitzgerald, MD:

The dishonest science here in the U.S. has denied chronic Lyme which stifled needed research to find a curative approach. Now the rest of the world is suffering. Lyme disease belongs in the same health threat category as AIDS.

Carl Tuttle is the organizer of the petition calling for a congressional investigation into the mishandling of Lyme disease. There are nearly 60,000 signatures from all across America and over twenty other countries. The primary focus of this petition has been to expose the deception and scientific misconduct while highlighting the fact that Lyme is life-threatening/life-altering ruining lives worldwide while foreign health officials follow what has been deceitfully established here in the United States.

Calling for a Congressional investigation of the CDC, IDSA and ALDF

There are now over a thousand pages of comments from horribly disabled Lyme patients all across America.

Comment file:

A congressional investigation is long overdue Representative Smith, just as Senator Ted Kennedy exposed the CDC’s Tuskegee Syphilis Crime.

The study of untreated syphilis in the negro male.


Please initiate a congressional investigation of the CDC, IDSA and American Lyme Disease Foundation with subpoena power to expose the motivation behind the downplaying of a disease destroying countless lives nationwide so that this travesty will never be repeated. Why was evidence of persistent infection suppressed for three decades?

Important: You or a loved one is just a single tick bite away from experiencing this travesty.

Respectfully Submitted,

Carl Tuttle (Representing New Jersey Lyme Patients who have signed the petition)

Lyme Endemic Hudson, NH

References: (Please read them!)

1. Cardiac Tropism of Borrelia burgdorferi: An Autopsy Study of Sudden Cardiac Death Associated with Lyme Carditis. (March 2016)


“Fatal Lyme carditis caused by the spirochete Borrelia burgdorferi rarely is identified. Here, we describe the pathologic, immunohistochemical, and molecular findings of five case patients.”

2. CDC Case Study #1: Three Sudden Cardiac Deaths Associated with Lyme Carditis:

3. CDC Case Study #2: A case report of a 17-year old male with fatal Lyme carditis

4. Professor Neil Spector: Duke physician uses near-death experience to encourage patient self-advocacy

Dr Neil Spector from Duke University required a heart transplant after his Lyme disease went undiagnosed for four years.

5. Nashua Mom in the ‘Lyme Light’ on Katie Couric Show

Fifth-grade teacher Kelly Downing was paralyzed from the neck down and interviewed by Katie Couric.

6. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma (Cancer)

Specific DNA sequences of Borrelia burgdorferi were identified in cutaneous lesions from 9 patients (follicle center lymphoma: 3/20; immunocytoma: 3/4; marginal zone B-cell lymphoma: 2/20; diffuse large B-cell lymphoma: 1/6).

7. Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis.

41 of 100 patients under surveillance for persistent LB in an endemic area were positive for urinary OspA protein after antibiotic treatment.

8. Culture evidence of Lyme disease in antibiotic treated patients living in the Southeast.
Rudenko and colleagues reported culture confirmation of chronic Lyme disease in 24 patients in North Carolina, Florida, and Georgia. All had undergone previous antibiotic treatment.

9. DNA sequencing diagnosis of off-season spirochetemia with low bacterial density in Borrelia burgdorferi and Borrelia miyamotoi infections.

Faulty/misleading antibody tests landed a sixteen year old male in a psychiatric ward when his lab results did not meet the CDC’s strict criteria for positive results. His Western blot had only four of the required five IgG bands. Subsequent DNA sequencing identified a spirochetemia in this patient’s blood so his psychiatric issues were a result of neurologic Lyme disease misdiagnosed by antiquated/misleading serology. This patient was previously treated with antibiotics.

10. Granulomatous hepatitis associated with chronic Borrelia burgdorferi infection: a case report
The patient had active, systemic Borrelia burgdorferi infection and consequent Lyme hepatitis, despite antibiotic therapy.

11. Scotty Shelton and Persistent Infection in Saginaw MN

“Scotty’s brain (cerebral cortex) was positive for Borrelia burgdorferi and Borrelia myamotoi, his testicle is positive for Bb. We are now testing other tissues. Seven years of antibiotics and 3.5 years of natural treatments (along with antibiotics) and he was highly highly positive.”

12. Congenital Transmission of Lyme/TBD

13. Wheelchair-Bound Girl Calls Blessing By Pope Francis ‘Most Precious Moment Of My Life’
NEW YORK (CBSNewYork) — A 12-year-old girl who has been confined to a wheelchair since being diagnosed with Lyme disease said meeting Pope Francis as he arrived in New York Thursday was “the most precious moment of my life.”